Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Early Improvement of Affective, Fatigue and Allodynic Symptoms in a Cohort of Resistant Migraineurs Treated with Anti-CGRP/R Antibodies

Alessandra Della Vecchia
ORCID logo ,
Ciro De Luca
* ,
Lucrezia Becattini
,
Letizia Curto
,
Elena Ferrari
,
Gabriele Siciliano
ORCID logo ,
Sara Gori
,
Filippo Baldacci
ORCID logo
Version 1 : Received: 1 February 2024 / Approved: 2 February 2024 / Online: 2 February 2024 (04:54:08 CET)

A peer-reviewed article of this Preprint also exists.

Della Vecchia, A.; De Luca, C.; Becattini, L.; Curto, L.; Ferrari, E.; Siciliano, G.; Gori, S.; Baldacci, F. Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients. Biomedicines 2024, 12, 677. Della Vecchia, A.; De Luca, C.; Becattini, L.; Curto, L.; Ferrari, E.; Siciliano, G.; Gori, S.; Baldacci, F. Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients. Biomedicines 2024, 12, 677.

Abstract

Objective: The study aimed to evaluate the effects of monoclonal antibodies (mAbs) acting on the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP/R mAbs) on comorbid symptoms of depression, anxiety, and fatigue in migraine patients resistant to traditional prophylaxis. Methods: The study was an open-label prospective study assessing comorbidities in patients with high frequency (HFEM) and chronic migraine (CM), medication overuse headache (MOH), and resistance to traditional prophylaxis treated with anti-CGRP/R mAbs for 3 months. Results: 77 patients were enrolled with either HFEM (21%) or CM (79%) with or without MOH (56% and 44% respectively). We identified 21 non-responders (27%) and 56 responders (73%), defined on the reduction ≥ 50% of headache frequency. The two groups were highly homogeneous for investigated comorbidities. Disease severity in terms of headache frequency, migraine-related disability, and affective comorbid symptoms were reduced in both groups with different thresholds; allodynia and fatigue were ameliorated only in responders. Conclusion: anti-CGRP/R antibodies improve pain together with affection, fatigue, and sensory sensitization in migraine patients.

Keywords

migraine; depression; anxiety; fatigue; comorbidities; monoclonal antibodies anti-CGRP/R

Subject

Medicine and Pharmacology, Neuroscience and Neurology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.